Caris Life Sciences Inc. Earnings Dividend

Caris Life Sciences Inc.’s revenue jumped 81.31% since last year same period to $181.4Mn in the Q2 2025. On a quarterly growth basis, Caris Life Sciences Inc. has generated 50.02% jump in its revenue since last 3-months.

Caris Life Sciences Inc.’s net profit fell -8.47% since last year same period to $-71.79Mn in the Q2 2025. On a quarterly growth basis, Caris Life Sciences Inc. has generated 30.02% jump in its net profits since last 3-months.

Caris Life Sciences Inc.’s net profit margin jumped 40.18% since last year same period to -39.58% in the Q2 2025. On a quarterly growth basis, Caris Life Sciences Inc. has generated 53.35% jump in its net profit margins since last 3-months.

Caris Life Sciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.1 - a 171.43% jump from last quarter’s estimates.

Caris Life Sciences Inc.’s earning per share (EPS) estimates for the current year stand at 0.1.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Caris Life Sciences Inc.’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Caris Life Sciences Inc.’s return on equity (ROE) stands at -0.45.